The obvious question—even a fifth grader would ask—was: would it work without the statin? Why wasn’t a statin-intolerant branch included in the study? Missing this critical piece has cost people billions of dollars. If that’s not gross incompetence, I don’t know what is.
I told you why the company did what they did. Amarin only ran Reduce It because the FDA required it to be in progress to get the Anchor label approved so they copied Jelis, narrowed the focus and started enrollment. The Anchor label was a blockbuster drug and the company was guaranteed sold pending the Anchor label approval. Reduce It was NEVER the goal, just a means to the Anchor end.
Market Data 
Markets 
AI
